Key clinical point: Prognostic marker analysis using FISH is infrequently performed.
Major finding: High-risk groups of patients with del(17p) and mutated TP53, received chemoimmunotherapy 34% and 26% of the time, respectively.
Study details: Retrospective database analysis of 840 patients from the informCLL registry.
Disclosures: The study was sponsored by an AbbVie Company and Janssen. The authors reported consulting and grants from these and other pharmaceutical companies.
Mato AR et al. Clin Lymphoma Myeloma Leuk. 2020;20(3):174-83.